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WS6.1 Longitudinal associations between FEV1 and HbA1c in a
UK cohort of young people with cystic ﬁbrosis
R.M. Williams1,2, T. Rootsey3, K.K. Ong4, D. McShane1, L. Shelby1. 1Cambridge
University Hospitals NHS Foundation Trust, Childrens Services, Cambridge, United
Kingdom; 2University of Cambridge, Paediatrics, Cambridge, United Kingdom;
3University of Cambridge, School of Clinical Medicine, Cambridge, United Kingdom;
4University of Cambridge, MRC Epidemiology Unit, Cambridge, United Kingdom
Objectives: To interrogate the UK national data set and explore longitudinal relation-
ships between FEV1, HbA1c and OGTT parameters in young people with CF up to
the age of 23 years.
Methods: The UK CF data set (2007 to 2012) recording annual measurements of
height, weight, BMI, % predicted FEV1 & FVC, HbA1c and 2hr glucose (2hrGlu)
(>10 yr only) was interrogated. HbA1c values >6.5% and 5.7−6.5% were used to deﬁne
‘undiagnosed’ DM and PD respectively, in patients not labelled as having CFRD. Data
from cases with known CFRD and DM were censored. Longitudinal models analysed
%FEV1 and %FVC as dependent variables, and HbA1c or 2hrGlu, BMI SDS, and age
as covariates in patients with HbA1c in the PD range.
Results: 2105 patients (1097 males, 87.9% with DF508 mutations, median (range)
age 13.7 (5.6−22) y, mean±SD BMI Zscore −0.11±1.1, %FEV 82.1±20.3 at ﬁrst visit
were included. Median (range) follow up was 3 (1−5) years. 2hrGlu was available in a
subgroup (n = 636). Changes in HbA1c (Table 1), but not 2hrGlu (slope −0.1, p = 0.3),
within the PD range (5.7−6.5%) were inversely associated with %FEV1.
Table 1. Univariate longitudinal models incorporated
Dependent
variable
Slope
(per % higher HbA1c)
P value 95% Conﬁdence interval
%FEV1 −2.9 0.016 −5.1 to −0.5
%FVC −2.1 0.08 −4.4 to 0.3
Conclusion: In this large UK data set, longitudinal increases in HbA1c within the PD
range were associated with declining lung function. Our ﬁndings support the rationale
for trials to intervene early to manage hyperglycaemia in young CF patients with PD.
Acknowledgement: We are grateful to the CF trust for sharing the UK national data
set. https://www.cysticﬁbrosis.org.uk/
WS6.2 Glucose tolerance in pediatric patients with cystic ﬁbrosis
L. Zazzeron1, S. Gambazza1, C. Colombo1. 1Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Cystic Fibrosis, Milan, Italy
Background: Cystic ﬁbrosis (CF)-related diabetes (CFRD) is a leading com-
plication of CF and is associated with pulmonary and nutritional deterioration.
Pathogenetic mechanism include insulin deﬁciency and insulin resistance.
Objectives: To evaluate glucose tolerance in pediatrics patients with CF and to
deﬁne a possible role of puberty in changing the status of glucose tolerance.
Methods: Data of CF patients who performed an oral glucose tolerance test
(OGTT) in the period 2003–2013 were collected. Glucose, insulin and C-peptide
concentrations were determined every 30 minutes for 3 hours. The area under the
glucose and insulin curve (AUC), the index of insulin resistance (HOMA-IR) and
the insulinogenic index (IG) were also calculated.
Results: We analyzed OGTT of 173 CF patients [91 females; median age (IQR)
13.2 yrs (2.4); 91 pre-pubertal (8−12 yrs) and 82 pubertal (13−17 yrs)]. 12% of
patients had glucose intolerance, 5% had diabetes without fasting hyperglycemia,
1% had diabetes with fasting hyperglycemia and 6% had indeterminate glucose
tolerance. There was no signiﬁcant differences in HOMA-IR, IG, FEV1%pred.
and BMI percentile among different tolerance categories. In contrast pubertal
patients had higher HOMA-IR and IG than pre-pubertal (P = 0.001 and P = 0.006,
respectively) and a trend towards higher AUC (ins0−120).
Conclusion: The data suggest that glucose tolerance status in our CF pediatric
population is not related to pulmonary function and nutritional status. The degree
of insulin resistance seems to increase around pre-puberty.
WS6.3 Subtle defects in glucose metabolism prior to development of
diabetes in patients with cystic ﬁbrosis
L. Marko1, K. Hershkop1, N. Eshel1, H. Eliashar Iron2, M. Cohen2, E. Kerem2,
R. Weiss1. 1Hebrew University, Jerusalem, Israel; 2Hadassah Medical Center
Mount Scoupus, Jerusalem, Israel
Cystic ﬁbrosis related diabetes (CFRD) is a common co-morbidity in people
with CF. The underlying pathophysiology of CFRD has not been revealed. We
hypothesized that it might be associated with an abnormal gut derived hormonal
proﬁle, speciﬁcally of lower incretin hormone responses, prior to development of
CFRD.
Ten non-diabetic CF patients (5F/5M) and nine healthy controls underwent an oral
glucose tolerance test (OGTT) for evaluation of insulin secretion, sensitivity and
incretin dynamics.
Fasting and 2-hour glucose levels of patients with CF were signiﬁcantly higher
compared to healthy controls. In the patients with CF the peak glucose occurred
later (60 min vs. 30 min in controls) and was higher (205.5±12.8mg/dL vs.
117.2±9.88mg/dL compared to normal controls. Insulin levels were signiﬁcantly
lower in the CF group at 30-min, compared to control group. C-peptide levels
were signiﬁcantly lower in the CF group at fasting and all time points and they
had a lower and delayed peak compared to controls. AUC for GLP-1and GIP
was signiﬁcantly lower for CF patients compared to control (p = 0.02, p = 0.04
respectively). CF patients had lower insulin sensitivity (p = 0.022), a lower acute
insulin response (p< 0.0001) and the oral disposition index was signiﬁcantly lower
in CF patients compared to controls (p< 0.0001) as well as the insulin clearance
(p = 0.002).
We propose that impaired incretin hormone responses is an additional contributor
to the pathophysiology of CFRD. This may be due to lower secretion responses or
due to reduced effects at the cellular level.
WS6.4 A placebo-controlled trial of insulin therapy with or without
adjuvant metformin in patients with cystic ﬁbrosis-related
diabetes (CFRD)
J.M.W. de Lind van Wijngaarden-van den Berg1, R. van der Meer1,
H.G.M. Heijerman1. 1Haga Teaching Hospital, Pulmonology, Adult Cystic
Fibrosis Center, The Hague, Netherlands
Objectives: Diabetes is a major co-morbidity in patients with Cystic Fibrosis (CF)
with a prevalence of 31% in our adult CF population and is associated with clinical
deterioration. CFRD consists of both insulin deﬁciency and ﬂuctuating insulin
resistance. We hypothesized that adding metformin to insulin therapy results in
a better management of CFRD. Aim of this study was to investigate the effect of
adjuvant metformin therapy on insulin need and glycaemic control in CFRD.
Methods: In this prospective randomized triple-blind crossover placebo-controlled
study, 17 patients received insulin therapy and were randomized for either receiving
adjuvant metformin or placebo during the ﬁrst 3-month therapy period. After a four
week wash-out, patients were interchanged to the other therapy regimen for a second
3-month therapy period. Study parameters were insulin need and blood HbA1c and
glucose levels.
Results: 14 patients completed the study. The median number of units insulin
administered per day was signiﬁcantly lower during the metformin study period in
comparison to the placebo period (respectively 19 IE/day and 26 IE/day, p = 0.015).
The lowering was more outspoken in patients with high insulin needs. HbA1c
remained unchanged between both treatment periods (51.5 versus 55mmol/mol,
p = 0.237). Glucose proﬁles measured by continuous glucose monitoring were more
stable during the metformin treatment.
Conclusion: In patients with CFRD, insulin need lowered and glucose levels were
more stable after adding metformin to their standard therapy.
